Aetna modified CPB 0968 for peanut oral immunotherapy (Palforzia), effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its peanut immunotherapy coverage policy under CPB 0968 Aetna system. The change directly affects how you bill for Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp) and the supporting services tied to administration — including CPT codes 90473 and +90474, HCPCS codes H0033 and J2357, and the peanut-specific IgE epitope test billed under CPT 0165U. If your practice manages peanut allergy patients or works with allergists and immunologists billing Aetna, this policy deserves attention before claims go out.
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Peanut Immunotherapy |
| Policy Code | CPB 0968 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Allergy & Immunology, Pediatrics, Primary Care (referral/co-management) |
| Key Action | Audit all active Palforzia patients for age-based eligibility and confirm prescriber specialty documentation before billing |
Aetna Peanut Immunotherapy Coverage Criteria and Medical Necessity Requirements 2025
Aetna's coverage policy for Palforzia is tighter than most payers' standard allergy coverage. Medical necessity hinges on six specific conditions — and all of them must be met simultaneously. Miss one, and the claim denies.
First, the diagnosis must be confirmed by serum IgE levels or skin prick testing. A clinical history of peanut allergy alone doesn't satisfy this criterion. Your documentation must show objective test results — not just a note that says "patient reports peanut allergy."
Second, Palforzia must be used alongside a peanut-avoidant diet. If your chart notes don't document that the prescribing allergist or immunologist counseled the patient on avoidance, you're leaving the door open for a claim denial on medical necessity grounds.
Third, the member cannot have uncontrolled asthma, eosinophilic esophagitis, or other eosinophilic gastrointestinal disease. This exclusion is firm. Document that the prescriber evaluated and ruled out these conditions before initiating treatment.
Age Criteria: The Detail That Will Catch Billing Teams Off Guard
The age rules in this coverage policy are not symmetric, and that asymmetry matters for billing.
For initial dose escalation, the member must be between 1 and 17 years of age. Adults are not covered for this phase. For up-dosing and the maintenance phase, the member must be 1 year of age or older — which does include adults who completed initial dose escalation as a minor and are continuing therapy.
That distinction is real and consequential. A 19-year-old continuing Palforzia maintenance therapy is covered. A 19-year-old starting from scratch with initial dose escalation is not. Make sure your patient screening catches this before you initiate billing.
Prescriber Specialty and Setting Requirements
Aetna requires that Palforzia be prescribed by — or in consultation with — an allergist or immunologist. A general pediatrician or primary care physician writing a standalone Palforzia prescription without an allergist's involvement creates a medical necessity documentation problem.
The setting requirement adds another billing layer. Initial dose escalation and the first dose of each up-dosing level must be administered in a healthcare setting equipped to monitor patients and manage anaphylaxis. This is not optional, and it affects where you report administration codes. Palforzia oral immunotherapy billing for those doses needs to reflect administration in a monitored clinical setting — not an office visit where observation capability isn't documented.
Prior authorization is strongly implied by the clinical necessity criteria here. If you're billing Palforzia for Aetna members and haven't confirmed prior auth requirements with your specific plan, do that now. The criteria are specific enough that Aetna will check documentation closely on audit.
Aetna Peanut Immunotherapy Exclusions and Non-Covered Indications
Aetna's position is clear: all indications for Palforzia not specifically described in the initial approval criteria are considered experimental, investigational, or unproven.
That means any off-label use — including use in adults for initial dose escalation, or use in patients with eosinophilic GI disease — will not meet medical necessity standards. Don't expect a successful appeal without new clinical evidence that directly rebuts Aetna's criteria.
The policy does not extend coverage to other forms of peanut immunotherapy beyond Palforzia. If another oral immunotherapy product or a sublingual or subcutaneous peanut desensitization approach is being used, CPB 0968 does not cover it.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Palforzia for peanut allergy — ages 1–17, initial dose escalation | Covered | Z91.010, T78.01xA–T78.01xS | Must have confirmed IgE or skin prick test; peanut-avoidant diet required |
| Palforzia for peanut allergy — age 1+, up-dosing phase | Covered | Z91.010, T78.01xA–T78.01xS | Includes adults continuing from earlier escalation; first dose of each level must be in monitored setting |
| Palforzia for peanut allergy — age 1+, maintenance phase | Covered | Z91.010, T78.01xA–T78.01xS | Peanut-avoidant diet must continue; no uncontrolled asthma or eosinophilic GI disease |
| Palforzia initial dose escalation in adults (age 18+) | Not Covered | — | Age criterion not met for initial escalation phase |
| Palforzia in patients with uncontrolled asthma | Not Covered | — | Explicit exclusion; document ruling out prior to treatment |
| Palforzia in patients with eosinophilic esophagitis or eosinophilic GI disease | Not Covered | — | Explicit exclusion |
| Other peanut immunotherapy approaches (non-Palforzia) | Experimental / Not Covered | — | Policy limited to Palforzia specifically |
| All other indications not listed above | Experimental / Investigational | — | Aetna's blanket exclusion language applies |
Aetna Peanut Immunotherapy Billing Guidelines and Action Items 2025
The effective date of September 26, 2025 is already here. If your team hasn't updated workflows around Palforzia billing, do it now.
| # | Action Item |
|---|---|
| 1 | Audit all active Palforzia patients for age-based eligibility. For any patient who was a minor at escalation but is now 18 or older, confirm they're in the up-dosing or maintenance phase. Patients who need to restart initial escalation as adults fall outside coverage. Flag those cases before the next claim goes out. |
| 2 | Confirm prescriber documentation shows allergist or immunologist involvement. Pull a sample of recent Palforzia claims and check that the prescribing provider is an allergist or immunologist — or that there's a documented consultation on file. Claims written solely by primary care without that consultation trail are vulnerable. |
| 3 | Document IgE or skin prick test results in every patient record before billing. A diagnosis code alone doesn't satisfy the medical necessity criteria. Your billing team should flag any chart missing objective allergy testing results and hold claims until documentation is complete. |
| 4 | Verify prior authorization status on every active Palforzia patient. The criteria are specific enough that Aetna will look for documentation on audit. If you're not sure how prior auth applies to your specific Aetna plan mix, talk to your compliance officer before claims go out. |
| 5 | Check setting documentation for initial escalation and first up-dosing doses. CPT 90473 and +90474 for immunization administration by oral route — and HCPCS H0033 for direct-observation oral medication administration — should reflect administration in a monitored clinical setting. If your charge capture is pulling those codes from an unmonitored visit, fix the workflow. |
| 6 | Review chart documentation for peanut-avoidant diet counseling. This is a required element for coverage, but it's easy to miss in documentation audits. Add a check for diet counseling documentation to your Palforzia claim review process. |
| 7 | Don't bill CPT 0165U without understanding what it covers. CPT 0165U is a proprietary lab code for peanut allergen-specific IgE quantitative assessment of 64 epitopes. This is a specialized diagnostic — not a routine IgE panel. Make sure your lab or ordering provider is clear on when this code applies versus standard IgE testing, and check whether Aetna covers it separately under this policy or requires separate authorization. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Peanut Immunotherapy Under CPB 0968
CPT Codes
| Code | Type | Description |
|---|---|---|
| 0165U | CPT | Peanut allergen-specific IgE and quantitative assessment of 64 epitopes using enzyme-linked immunosorbent assay (ELISA) |
| 90473 | CPT | Immunization administration by intranasal or oral route; first vaccine (single or combination vaccine/toxoid) |
| +90474 | CPT | Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) — add-on code, list separately |
HCPCS Codes
| Code | Type | Description |
|---|---|---|
| H0033 | HCPCS | Oral medication administration, direct observation |
| J2357 | HCPCS | Injection, omalizumab, 5 mg |
Note on J2357: Omalizumab (Xolair) is a monoclonal antibody sometimes used as an adjunct in food allergy desensitization protocols. Its inclusion in CPB 0968 signals that Aetna may consider it in context with peanut immunotherapy regimens. If your team bills J2357 for Aetna members in an allergy setting, confirm whether the claim context aligns with this policy or requires separate authorization under a different CPB. If you're uncertain, loop in your compliance officer before submitting.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| T78.01xA – T78.01xS | Anaphylactic reaction due to peanuts (full range of encounter suffixes) |
| Z91.010 | Allergy to peanuts |
Use Z91.010 as the primary diagnosis for routine Palforzia administration claims. The T78.01x range covers anaphylactic reaction — relevant when documenting the clinical rationale for treatment or when an adverse event occurs during an administration visit. Match the 7th character suffix to the encounter type: A for initial, D for subsequent, S for sequela.
Get the Full Picture for CPT 90473
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.